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Abdurrahman COﬁKUN1
Burcu ÖZDEM‹RL‹2
Ramazan MEM‹ﬁO⁄ULLARI1

Abstract: In this study, we aimed to investigate the role of pregnancy-associated plasma protein-A (PAPP-A)
as insulin-like growth factor binding protein-4 (IGFBP-4) protease in epilepsy patients. We studied 16 epilepsy
patients and 10 healthy controls. Serum PAPP-A levels of epilepsy patients (6.8 ± 3.2 mU/L) were higher than
of the control group (5.1 ± 1.9 mU/L), but the difference was not statistically significant (P > 0.05). We
concluded that PAPP-A may increase the bioavailability of insulin-like growth factors (IGFs) due to decreased
neurogenesis and synthesis of IGFs in chronically epilepsy patients.
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Özet: Bu çal›ﬂmada insulin benzeri büyüme faktörü ba¤lay›c› protein-4 (IGFBP-4) proteaz olarak bilinen
gebelikle iliﬂkili plazma protein A’n›n (PAPP-A) epilepsili hastalardaki rolünü araﬂt›rmay› amaçlad›k. Çal›ﬂmaya
16 epilepsi hastas› ve 10 sa¤l›kl› birey al›nd›. Epilepsili hastalarda serum PAPP-A düzeyleri (6,8 ± 3,2 mU/L)
kontrol grubuna göre (5,1 ± 1,9 mU/L) yüksek bulunmas›na ra¤men aradaki fark istatistiksel olarak anlaml›
bulunmad› (P > 0.05). PAPP-A’n›n epilepsili hastalarda azalan insülin benzeri büyüme faktörlerinin (IGF)
sentezi ve nörogenez durumunda IGF’lerin etkinli¤ini art›rmada rol alabilece¤ini düﬂünmekteyiz.
Anahtar Sözcükler: Beyin tümörü, Epilepsi, IGF-I, IGFBP, IGFBP-4, Nörogenez, PAPP-A

Introduction
The insulin-like growth factor (IGF) axis is a multi-component network of molecules
that is ubiquitously involved in the regulation of growth, proliferation, and differentiation
of a variety of cell types.. This axis includes two major ligands, IGF-I and IGF-II,, the type
1 and type 2 IGF receptors, a family of at least six high-affinity IGF binding proteins
(IGFBPs) that determine the bioavailability of IGFs,, and a group of IGFBP proteases that
cleave IGFBPs and hence modulate the bioavailability of IGFs (1).
IGF-dependent IGFBP-4 protease activity has been described in a variety of cells,
including fibroblasts,, osteoblasts,, endometrial stromal cells,, and granulosa cells (1). The
IGF-dependent IGFBP-4 protease has been postulated to amplify local IGF-I activity in
wound healing, vascular repair, bone remodeling, and development of the dominant
follicle (2). IGFBP-4 protease was purified from human fibroblasts and identified as
pregnancy-associated plasma protein-A (PAPP-A) (2).
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During pregnancy, PAPP-A is produced in high concentrations by trophoblasts, and
maternal serum assessment between 11 and 14 weeks of gestation has significant utility
in screening for Down syndrome (DS) and other chromosomal anomalies. In addition to
pregnancy, the clinical value of PAPP-A continues to grow as new data become available.
It has been reported that the occurrence of epilepsy in DS in childhood is not different
from that in the general population, but infantile spasms are prevalent in DS (3).
However, in adult DS patients, epilepsy is more common than in the normal population
and the possible mechanisms have not been adequately explored (4). In the present study,
we aimed to search the role of PAPP-A as IGFBP-4 protease in epilepsy patients.
Blood samples were drawn from the antecubital vein from 16 epilepsy patients (9 men
and 7 women, mean age 36 ± 11 years) and from 10 control subjects (7 men and 3
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women, mean age 29 ± 8 years). Blood samples were
collected in sterile tubes without additives and centrifuged
at 1500 x g for 10 min in 1 hour. Following
centrifugation, the serum aliquots were stored at -20oC
until analysis. All samples were processed within 1 month.
Serum PAPP-A levels were determined by an ultrasensitive
enzyme-linked immunosorbent assay (ELISA) (Diagnostic
Systems Laboratories, Texas-USA). The minimum
detection limit of the method was 0.24 mU/L and the
coefficient of variation (CV) was 4.80%.
Data were expressed as the mean ± SD. The un-paired
Student’s t test was used to evaluate the significance of
difference between epilepsy (all patients) and control
groups. Values of P < 0.05 were considered as statistically
significant.
Serum PAPP-A levels of epilepsy patients (6.8 ± 3.2
mU/L) were higher than of the control group (5.1 ± 1.9
mU/L), but the difference was not statistically significant (P
> 0.05).
Discussion
IGFs regulate both normal and malignant brain growth
and promote the proliferation of oligodendrocytes and
myelin synthesis (5). IGFs are also anabolic regulators in
astrocytes and neurons. Specific receptors for IGFs are
found in central nervous system (CNS) tumors, and various
IGFBPs are also secreted by these tumors (6).
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Among the six IGFBPs, IGFBP-4 is unique in inhibiting
IGF actions (7). PAPP-A, as IGFBP-4 protease, degrades
IGFBP-4 and increases the local concentration and
consequently the bioavailability of IGF-I (2). PAPP-A is also
potentially proatherosclerotic, and high serum levels have
been observed in patients with acute coronary syndromes
(8). It has been shown that status epilepticus and
hippocampal injury induce new neuron production in the
dentate gyrus (9). However, Hattiangady and co-workers
(10) have demonstrated that a chronically epileptic
hippocampus has 53% less IGF-I in comparison to the adult
intact hippocampus. In the present study, no patient was in
status epilepticus when blood was drawn for PAPP-A.
Jacoby and co-workers (11) have demonstrated that
homozygous Galr1-/- mice have reduced circulating IGF-I
and exhibit spontaneous tonic-clonic seizures. Systemic
administration of kainic acid evokes acute seizure in the
hippocampal pathway that resembles temporal lobe epilepsy.
Kar and co-workers (12) have shown that administration of
kainic acid decreased IGF-I transiently in almost all regions of
the hippocampus. Taken together, it seems that epilepsy,
especially temporal lobe epilepsy, is accompanied with low
IGF-I serum levels and the IGF axis and related molecules
may play an important role in the pathophysiology of
epilepsy. We concluded that, in spite of not being statistically
significant, elevated PAPP-A in epilepsy patients may
increase the bioavailability of IGFs due to decreased
neurogenesis and synthesis of IGFs in chronically epileptic
patients. However, this hypothesis needs further studies.
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